You are here

CELDARA MEDICAL, LLC

Company Information
Address
16 CAVENDISH CT
LEBANON, NH 03766-1441
United States


http://www.celdaramedical.com

Information

UEI: MMVKQXZUBMQ7

# of Employees: 15


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No




Success Stories

  1. SBIR-STTR Success: Celdara Medical LLC

    How much good could you do with $30 billion dollars and the smartest people in the world? That is the question that the founders of Celdara Medical asked themselves when beginning the company in 2008.Each year, the National Institutes of Health allocates $30 billion to the best and brightest...

Award Charts




Award Listing

  1. Antimicrobial peptides to combat MDR ESKAPE pathogens

    Amount: $298,691.00

    Project Summary Bacterial resistance has reached alarming levels in the US and other parts of the world in the past decadeThe increase in bacterial infection with drug resistantDRpathogens are resulti ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  2. Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM

    Amount: $224,170.00

    Project Summary Acute Kidney InjuryAKIis common in hospitalized patients after severe illness or following major surgeriessuch as cardiovascular surgeryThe incidence of AKI in critically ill patients ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  3. DRIVEN: Accelerating Medical Entrepreneurship in the Northeast

    Amount: $3,167,970.00

    Project Summary This project describes the formation, launch and operation of the DRIVEN Accelerator Hub, with the express goal of reducing morbidity and mortality by increasing the number of medical ...

    STTRPhase II2019Department of Health and Human Services National Institutes of Health
  4. Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus

    Amount: $595,060.00

    PROJECT SUMMARY The filovirusesfamily Filoviridaecomprising five ebolavirusesa cuevavirusand two Marburg virusesare negative strand RNA viruses that cause severe hemorrhagic fever with up tohuman case ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  5. Specificity and safety of a targeted therapy against triple negative breast cancer

    Amount: $300,000.00

    PROJECT SUMMARY ABSTRACT Despite recent advances in the treatment of breast cancerBCthere is a pressing unmet medical need as BC remains the second leading cause of cancer related deaths among womenIn ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  6. Complex 3-Dimensional in vitro Human Skin Tissue Models for Scleroderma

    Amount: $1,488,101.00

    PROJECT SUMMARY Sclerodermasystemic sclerosisSScis an autoimmune disease of unknown etiology that is characterized by vascular dysfunctionfibrosisand inflammationOne in three patients dies withinyears ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  7. Discovery of novel helminth immunomodulatory proteins for autoimmune diseases

    Amount: $598,006.00

    This contract aims to identify novel parasite derived protein candidates as biologics to treat Crohn s and other diseases with high healthcare costs and no truly long term effective treatment optionsW ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  8. Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF

    Amount: $1,500,081.00

    DESCRIPTIONprovided by applicantIdiopathic pulmonary fibrosisIPFkills aboutpersons in the United States each yearThere are currently aroundAmericans afflicted with this fatal disease that typically re ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  9. Development of GIFT4: a B cell focused immunotherapy for cancer

    Amount: $1,999,085.00

    Project Summary Our goal is to develop a novel immunotherapy for the treatment of melanomaand potentially a wide array of tumorsAlthough surveillance by the immune system eliminates cancer cells in so ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  10. Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome

    Amount: $800,093.00

    Project Summary Rodent borne viral outbreaks are increasing in both frequency and impactAs weather patterns evolverodent populations are affected and may multiply in areas where increased contact with ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government